A practical reference on LC-MS/MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
| Property | Value | Notes |
|---|---|---|
| WADA classification | S4 Hormone and Metabolic Modulators | Prohibited at all times in sport. |
| Drug approval status | Not approved in major jurisdictions | No accepted therapeutic indication. |
| Common detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Typical test matrix | Urine or blood | Urine is common in anti-doping testing. |
| Product labeling | Research chemical or supplement | Often not independently verified. |
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
The Vietnamese were locked in a civil war over the destiny of their post-colonial state after the ousting of the French and the surrender of Japan in 1945. The communist-controlled Viet Minh sought to consolidate power by terrorizing and purging rival Vietnamese nationalist groups amid the French reconquest. Tensions between the Viet Minh, led by Ho Chi Minh, and the French erupted into the First Indochina War in December 1946. From early on, the Vietnamese communists were deeply committed to a radical ideology, occasionally harboring ambitions to lead the world revolution. In 1949, Mao's communists took control of the north side of the China–Vietnam border, and began supporting the Democratic Republic of Viet Nam (DRV). Mark Lawrence and Frederik Logevall point out that "resurgent French colonialism became inextricably intertwined with Cold War tensions, especially in the years after 1949". American pressure on France after 1949 tried to force France to give priority to fighting communism, rather than fighting Vietnamese nationalism. The nationalist State of Vietnam (SVN), with Bảo Đại as Chief of State, was established and positioned within the anticommunist Western Bloc. With the recognition of the DRV by communist China and the Soviet Union, and the recognition of the SVN by the United States in 1950, the civil war and the colonial war in Vietnam became internationalized and intertwined with the global Cold War.
The English word saffron is a borrowing from French, first found in a Middle English text written around 1200 as saffran. It derives from the 12th-century Old French term safran, which comes from the Medieval Latin word safranum, and from the Persian زعفران zafarān. It originated from the older زر پران zarparān, meaning 'gold-strung' in reference to the flower's golden filaments or the rich golden hue it imparts as a spice.
Oscar Werner Tiegs FRS FAA (12 March 1897 – 5 November 1956) was an Australian zoologist whose career spanned the first half of the 20th century. His contribution to the division of the phylum arthropoda into two parts, one including insects, myriapods, and velvet worms, and the other including trilobites, crustaceans, and arachnids, is considered to be an important contribution to zoology. He was known for his ability to illustrate animals to great detail and obsession with microscopic observation of invertebrates. He is considered one of Australia's great zoologists and as having a permanent place in the history of zoology. He was a Doctor of Science (University of Adelaide), a Fellow of the Royal Society, and a founding Fellow of the Australian Academy of Science.
==== Kasukawa criteria ==== The Kasukawa criteria require a minimum of one of the common symptoms, a positive anti-RNP antibody, as well as one or more symptoms of the mixed symptoms in at least two of the three disease categories to qualify for a diagnosis of MCTD. It has a sensitivity of 75% and a specificity of 99.8%. Common symptoms:
Sources: en.wikipedia.org
==== 1966 White Paper: major cuts and a new name ==== This was followed by a large reduction and complete reorganisation, announced in the 1966 Defence White Paper and implemented from 1 April 1967, when the title Territorial and Army Volunteer Reserve (TAVR) was adopted. This abolished the former divisional structure of the TA. The size of the TAVR was to be reduced from 107,000 to under 50,000, with the infantry reduced from 86 to 13 battalions and the yeomanry (armoured units) from 20 to one. Units in the new TAVR were divided into various categories:
Like the more common EDTA, DTPA is predominantly used as chelating agent for complexing and sequestering metal ions. DTPA has been considered for treatment of radioactive materials such as plutonium, americium, and other actinides. In theory, these complexes are more apt to be eliminated in urine. It is normally administered as the calcium or zinc salt (Ca or Zn-DTPA), since these ions are readily displaced by more highly charged cations and mainly to avoid depleting them in the organism. DTPA forms complexes with thorium(IV), uranium(IV), neptunium(IV), and cerium(III/IV). In August 2004, the U.S. US Food and Drug Administration (USFDA) determined zinc-DTPA and calcium-DTPA to be safe and effective for treatment of those who have breathed in or otherwise been contaminated internally by plutonium, americium, or curium. The recommended treatment is for an initial dose of calcium-DTPA, as this salt of DTPA has been shown to be more effective in the first 24 hours after internal contamination by plutonium, americium, or curium. After that time has elapsed both calcium-DTPA and zinc-DTPA are similarly effective in reducing internal contamination with plutonium, americium or curium, and zinc-DTPA is less likely to deplete the body's normal levels of zinc and other metals essential to health. Each drug can be administered by nebulizer for those who have breathed in contamination, and by intravenous injection for those contaminated by other routes. Gadolinium (Gd3+)-DTPA compounds are MRI contrasting agents. DTPA under the form of iron(II) chelate (Fe-DTPA, 10–11 wt.
=== Results === The growing intensity of the civil war and a lack of international support eventually led the Rhodesian government to submit to an agreement with the UK in 1979. This led to internationally supervised elections, won by Zimbabwe African National Union – Patriotic Front and Robert Mugabe, establishing the internationally recognised Zimbabwe.
Sources: en.wikipedia.org
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.
Legality varies by country and context. It lacks marketing approval as a medicine in major countries. Sports organizations prohibit its use at all times.
A certificate of analysis may report identity, purity, and testing methods for a specific batch. It does not guarantee safety or legal status. Independent verification can confirm whether the material matches the label.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.